Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

19 evidence topics · 20 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.